{"organizations": [], "uuid": "44c4594a6730a475f0dbba39ebb01d97c554eeb5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sarepta-therapeutics-announces-par/brief-sarepta-therapeutics-announces-partnership-with-myonexus-therapeutics-idUSFWN1SA1CL", "country": "US", "domain_rank": 408, "title": "Sarepta Therapeutics Announces Partnership With Myonexus Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.232, "site_type": "news", "published": "2018-05-04T04:25:00.000+03:00", "replies_count": 0, "uuid": "44c4594a6730a475f0dbba39ebb01d97c554eeb5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sarepta-therapeutics-announces-par/brief-sarepta-therapeutics-announces-partnership-with-myonexus-therapeutics-idUSFWN1SA1CL", "ord_in_thread": 0, "title": "Sarepta Therapeutics Announces Partnership With Myonexus Therapeutics", "locations": [], "entities": {"persons": [{"name": "sarepta", "sentiment": "none"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "sarepta therapeutics inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "sarepta therapeutics", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Sarepta Therapeutics Inc:\n* SAREPTA THERAPEUTICS ANNOUNCES PARTNERSHIP WITH MYONEXUS THERAPEUTICS FOR THE ADVANCEMENT OF MULTIPLE GENE THERAPY PROGRAMS AIMED AT TREATING DISTINCT FORMS OF LIMB-GIRDLE MUSCULAR DYSTROPHIES\n* SAREPTA THERAPEUTICS INC - SAREPTA IS GRANTED EXCLUSIVE OPTION TO ACQUIRE MYONEXUS\n* SAREPTA THERAPEUTICS INC - A PHASE 1/2A STUDY OF MYO-101 IS SCHEDULED TO BEGIN IN MID-2018\n* SAREPTA THERAPEUTICS INC - COMPANIES PLAN TO REPORT ON 60-DAY BIOPSY DATA IN LATE-2018 OR EARLY 2019\n* SAREPTA - WILL MAKE UPFRONT PAYMENT OF $60 MILLION, ADDITIONAL MILESTONE PAYMENTS TO PURCHASE AN EXCLUSIVE OPTION TO ACQUIRE MYONEXUS\n* SAREPTA - IF ALL DEVELOPMENT-RELATED MILESTONE PAYMENTS ARE MET, CO TO MAKE PAYMENTS OF UP TO $45 MILLION OVER AN ABOUT TWO-YEAR EVALUATION PERIOD Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-04T04:25:00.000+03:00", "crawled": "2018-05-04T17:04:42.009+03:00", "highlightTitle": ""}